Drug Profile

RS 001 - WYZE Biotech

Alternative Names: RS-001 - WYZE Biotech

Latest Information Update: 03 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator WYZE Biotech
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Interleukins
Mechanism of Action Immunologic cytotoxicity; Interleukin 15 replacements; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Preclinical B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

25 Mar 2025 Preclinical trials in B-cell lymphoma in China (Parenteral) (NCT06894693)
25 Mar 2025 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in China (Parenteral) (NCT06894693)
25 Mar 2025 WYZE Biotech plans a phase I trial for B-cell lymphoma and Precursor-cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater) in April 2025 (Parenteral) (NCT06894693)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com